{
    "clinical_study": {
        "@rank": "45262", 
        "arm_group": [
            {
                "arm_group_label": "Tegaderm CHG clear dressing", 
                "arm_group_type": "Experimental", 
                "description": "Patients randomized to receive Tegaderm CHG clear dressing. All central line care will remain uniform between the two groups as dictated by the central line maintenance bundle currently directing central line care in our children's hospital."
            }, 
            {
                "arm_group_label": "Standard clear Tegaderm dressing", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients randomized to receive standard clear Tegaderm dressing. All central line care will remain uniform between the two groups as dictated by the central line maintenance bundle currently directing central line care in our children's hospital."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare Tegaderm CHG clear dressing to standard clear\n      Tegaderm IV dressing with regards to contact skin irritation in pediatric patients between\n      the ages of 2 months to 18 years with central venous access. Reducing the risk of central\n      line associated blood stream infections will also be assessed."
        }, 
        "brief_title": "CHG Dressings in Children With Central Lines", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Children With Central Venous Access", 
        "detailed_description": {
            "textblock": "In this prospective, randomized, cohort study, we plan on enrolling all patients 2 months to\n      18 years of age admitted with a central venous catheter expected to be in place for > 48\n      hours. Patients will be randomized to either receive 1) Tegaderm CHG clear dressing or 2)\n      standard clear Tegaderm IV dressing. All central line care will remain uniform between the\n      two groups as dictated by the central line maintenance bundle currently directing central\n      line care in our children's hospital. Study completion will occur at the time of central\n      line removal or discharge from the hospital, whichever comes first."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All patients 2 months to 18 years of age admitted with a central venous catheter\n             expected to be in place for > 48 hours.\n\n        Exclusion Criteria:\n\n          -  Patients with known allergies to chlorhexidine or Tegaderm and those previously\n             enrolled in this study will be excluded."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "18 Years", 
            "minimum_age": "2 Months"
        }, 
        "enrollment": {
            "#text": "326", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01955226", 
            "org_study_id": "Giuliano913"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tegaderm CHG clear dressing", 
                "description": "Tegaderm CHG clear dressing will be used in central line care and will remain uniform as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.", 
                "intervention_name": "Tegaderm CHG clear dressing", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Standard clear Tegaderm dressing", 
                "description": "Standard clear Tegaderm dressing will be used in central line care and will remain uniform as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.", 
                "intervention_name": "Standard clear Tegaderm dressing", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 27, 2013", 
        "location": {
            "contact": {
                "email": "john.giuliano@yale.edu", 
                "last_name": "John S Giuliano Jr, MD", 
                "phone": "203-785-4651"
            }, 
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06520"
                }, 
                "name": "Yale University"
            }, 
            "investigator": {
                "last_name": "John S Giuliano Jr, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Unit Based Comparison of Non- Versus Chlorhexidine-Impregnated Central Line Dressings", 
        "overall_contact": {
            "email": "john.giuliano@yale.edu", 
            "last_name": "John S Giuliano Jr, MD", 
            "phone": "203-785-4651"
        }, 
        "overall_official": {
            "affiliation": "Yale University", 
            "last_name": "John S Giuliano Jr, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Skin irritation will be assessed using the Scoring of patch tests according to the International Contact Dermatitis Research Group. Scores of 0 are defined as no irritation, 1/2-1+ as minor irritation whereas scores greater than or equal to 2+ will be classified as severe and will require dressing removal.\nThe clinical team will photograph each central line insertion site with every dressing change and save the most severe skin irritation photo for analysis. These pictures will be sequentially numbered and a master list will link them to each patient.", 
            "measure": "Skin Irritation", 
            "safety_issue": "No", 
            "time_frame": "Study completion (Study completion will occur at the time of central line removal or discharge from the hospital, whichever comes first). On average 2 weeks."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01955226"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Yale University", 
            "investigator_full_name": "John Giuliano", 
            "investigator_title": "Assistant Professor Pediatrics; Director, Pediatric Transport Program; Associate Director, Pediatric Intensive Care Unit", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Blood stream infections will be tallied and reported per 1,000 central line days. Infection is attributed to the line if a culture becomes positive when the line is in up to 48 hours after removal.", 
            "measure": "Blood Stream Infection", 
            "safety_issue": "No", 
            "time_frame": "Discharge (at 2 weeks or more)"
        }, 
        "source": "Yale University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}